Gen-Editing-Therapie (CRISPR/Cas12a) zeigt Erfolge gegen schwere Sichelzellenanämie – Fast alle Patienten (27 von 28 Patienten) haben eine funktionelle Heilung erreicht. Die Ergebnisse zeigten, dass sich die wichtigsten Blutzellen bei den meisten Patienten innerhalb eines Monats nach der Behandlung erholten.
https://newsroom.clevelandclinic.org/2026/04/01/gene-editing-therapy-shows-success-against-severe-sickle-cell-disease
2 Kommentare
**Gene Editing Therapy Shows Success Against Severe Sickle Cell Disease**
**Nearly all patients have achieved a functional cure**
New results from a clinical trial show promising outcomes for a gene-edited treatment for severe sickle cell disease, a genetic blood disorder with few curative options.
Conducted as part of the multicenter RUBY Trial, researchers published their latest findings in the New England Journal of Medicine. Remarkably, 27 out of 28 patients did not have any painful sickle cell crises after treatment, achieving what physicians call a „functional cure.“
In the trial, patients were treated with an experimental one-time gene editing cell therapy – Renizgamglogene autogedtemcel (reni-cel) – that modifies a patient’s own blood-forming stem cells to correct the mutation responsible for sickle cell disease. The novel therapy increases levels of fetal hemoglobin – which prevents red blood cells from forming into sickle-shaped cells – and improves overall hemoglobin levels, reducing complications from the disease.
The 28 patients – four of whom were treated at Cleveland Clinic Children’s – underwent a procedure where their stem cells were first collected for gene editing. They then received chemotherapy to clear their bone marrow, making room for the repaired cells which were later infused back into their body.
**The results showed that most patients saw key blood cells recover within a month after treatment** and by six months, average total hemoglobin levels rose to 13.8 g/dL, up from 9.8 g/dL before treatment – a level closer to what is seen in people without sickle cell disease. The average level of fetal hemoglobin (HbF) was 48.1%, and these levels remained stable over time.
For those interested, here’s the link to the peer reviewed journal article:
https://www.nejm.org/doi/10.1056/NEJMoa2415550
Not a surprise, we knew this to work in animals, and our cancers being different is not really the problem. Universally is that cancers hide from our immune system by mimicking normal cells, but give our immune system some materials that only cancer cells have, they bypass the whole thing. Same solution across the board.